Slagter, Astrid E.
Vollebergh, Marieke A.
Caspers, Irene A.
van Sandick, Johanna W.
Sikorska, Karolina
Lind, Pehr
Nordsmark, Marianne
Putter, Hein
Braak, Jeffrey P. B. M.
Meershoek-Klein Kranenbarg, Elma
van de Velde, Cornelis J. H.
Jansen, Edwin P. M.
Cats, Annemieke
van Laarhoven, Hanneke W. M.
van Grieken, Nicole C. T.
Verheij, Marcel
Funding for this research was provided by:
KWF Kankerbestrijding
Dutch Colorectal Cancer Group
F. Hoffmann-La Roche
Article History
Received: 20 August 2021
Accepted: 13 October 2021
First Online: 29 October 2021
Declarations
:
: N.C.T. van Grieken reported receiving grants from the Dutch Cancer Society and The Netherlands Organisation for Health Research and Development, and serving on an advisory board for Bristol-Myers Squibb and Merck Sharp and Dohme. H.W.M. van Laarhoven reported receiving grants/medication support from Bayer, BMS, Celgene, Janssen, Lilly, Merck, Nordic Pharma, Philips, Roche, Servier, and serving on an advisory board for BMS, Lilly, MSD, Nordic Pharma, Novartis, Servier E.P.M. Jansen, A. Cats and M. Verheij reported receiving grants from the Dutch Cancer Society, the Dutch Colorectal Cancer Group and Hoffmann La Roche.
: All the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all the patients.